Antiviral therapy prolongs survival in immune tolerant hepatitis B patients

Posted by on April 15, 2016 12:14 pm
Categories: health

A new study demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis).

Leave a Reply

Your email address will not be published. Required fields are marked *